No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
RXRX241213C12000
- 0.10
- 0.000.00%
15min DelayClose Dec 11 16:00 ET
0.00High0.00Low
0.10Open0.10Pre Close0 Volume17 Open Interest12.00Strike Price0.00Turnover501.42%IV59.84%PremiumDec 13, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.0994Delta0.0724Gamma75.70Leverage Ratio-0.0970Theta0.0000Rho7.52Eff Leverage0.0008Vega
Intraday
- 5D
- Daily
News
Hold Rating for Recursion Pharmaceuticals Amid Early Efficacy Signals and Financial Concerns
Why Recursion Pharmaceuticals (RXRX) Is the Worst ARK Stock to Buy According to Short Sellers
Needham Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $11
Promising Developments and Positive Outlook for Recursion Pharmaceuticals Drive Buy Rating
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $11 Price Target
Recursion Pharmaceuticals Analyst Ratings